---
schema_version: "secwatch.filing_event.v1"
accession: "0000950142-22-002339"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2022-07-28T23:59:59+00:00"
generated_at: "2026-06-24T07:36:57.194391+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals Chief Corporate Officer, General Counsel & Corporate Secretary resigns effective July 22, 2022

## Summary
- Alessandra Daigneault resigned as Chief Corporate Officer, General Counsel and Corporate Secretary, effective July 22, 2022.
- Resignation not due to any disagreement with management or board regarding operations, policies, or practices.
- Ms. Daigneault left to pursue other personal and professional interests.
- No successor named in the filing.

## SEC filing metadata
- accession: 0000950142-22-002339
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2022-07-28T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000095014222002339/0000950142-22-002339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000095014222002339/eh220274812_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950142-22-002339
- JSON: https://secwatch.observer/filing/0000950142-22-002339.json
- Plain text: https://secwatch.observer/filing/0000950142-22-002339.txt

## Key facts
- Executive change
  Alessandra Daigneault resigned as Chief Corporate Officer, General Counsel and Corporate Secretary at NRX Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Corporate Officer, General Counsel and Corporate Secretary
  source text: On July 22, 2022, Ms. Alessandra Daigneault resigned as Chief Corporate Officer, General Counsel and Corporate Secretary of NRx Pharmaceuticals, Inc. (the “Company”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000095014222002339/0000950142-22-002339-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.